Patrys receives R&D Tax Incentive refund
Filed with ASX · · 2 pages · English
Melbourne, Australia; 10 June 2021: Patrys Limited (ASX: PAB, “Patrys” or the “Company”), a therapeutic antibody development company, is pleased to announce that its wholly-owned subsidiary Nucleus Therapeutics Pty Ltd has received a $626,780 R&D Tax Incentive Refund for the 2019/2020 financial year. The Australian Government R&D Tax Incentive encourages companies to engage in R&D benefiting Austr
Earlier from Patrys
- Appendix 4C - Quarterly - 31 March 2021
- New United States patent granted for Patrys deoxymab assets
- Appendix 4D - Half Year Accounts - 31 December 2020
- Patrys Successfully Establishes PAT-DX1 Stable Cell Line
- Appendix 4C - Quarterly - 31 December 2020
Later from Patrys
- Paper highlights PAT-DX1 as potential brain cancer treatment
- Patrys Limited Announces Publication of PAT-DX1 Preclinical Data in JCI - Insight
- Response to ASX Query
- Full size deoxymab PAT-DX3 crosses the blood brain barrier
- PAT-DX1 Improves Survival in Model of Pancreatic Cancer
Follow Patrys into a list and get an email when it puts out news.
Follow Patrys